Premium
Antiviral drug resistance in human cytomegalovirus
Author(s) -
Chou S.
Publication year - 1999
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1034/j.1399-3062.1999.010204.x
Subject(s) - drug resistance , medicine , cytomegalovirus , human cytomegalovirus , virology , drug , genotype , foscarnet , viral shedding , disease , immunology , virus , ganciclovir , gene , viral disease , herpesviridae , pharmacology , biology , genetics
Drug‐resistant cytomegalovirus (CMV) should be considered when viral shedding persists after several weeks of therapy. The problem is most likely to arise in the setting of a severely immunosuppressed host with continuing or relapsing disease. Not all treatment failure can be attributed to drug resistance. The testing of CMV isolates for drug resistance in cell culture is time‐consuming and labor‐intensive, but recent advances in understanding of the genetics of resistance have resulted in rapid genotypic assays for specific mutations in the viral UL97 phosphotransferase or UL54 DNA polymerase genes that can predict resistance and cross‐resistance to specific drugs. This information may help in the selection of alternative therapy Note.